Clinical Trials Logo

Mixed Phenotype Acute Leukemia clinical trials

View clinical trials related to Mixed Phenotype Acute Leukemia.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05326516 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

A Study of SNDX-5613 in Combination With Chemotherapy in Participants With R/R Acute Leukemia

Start date: March 9, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the safety and tolerability of SNDX-5613 when given in combination with 2 different chemotherapy regimens in participants with relapsed/refractory acute leukemias harboring KMT2A rearrangement, KMT2A amplification, NPM1c, or NUP98r.

NCT ID: NCT03404193 Active, not recruiting - Clinical trials for Acute Myeloid Leukemia

Venetoclax and Decitabine in Treating Participants With Relapsed/Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome

Start date: January 18, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well venetoclax and decitabine work in treating participants with acute myeloid leukemia that has come back or does not respond to treatment, or with high-risk myelodysplastic syndrome that has come back. Drugs used in chemotherapy, such as venetoclax and decitabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT02828358 Active, not recruiting - Clinical trials for Mixed Phenotype Acute Leukemia

Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement

Start date: April 1, 2017
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies the side effects of azacitidine and combination chemotherapy in infants with acute lymphoblastic leukemia and KMT2A gene rearrangement. Drugs used in chemotherapy, such as methotrexate, prednisolone, daunorubicin hydrochloride, cytarabine, dexamethasone, vincristine sulfate, pegaspargase, hydrocortisone sodium succinate, azacitidine, cyclophosphamide, mercaptopurine, leucovorin calcium, and thioguanine work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving more than one drug may kill more cancer cells.